HomeCompareBDX vs ZBH

BDX vs ZBH: Dividend Comparison 2026

BDX yields 2.27% · ZBH yields 1.08%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BDX wins by $5.7K in total portfolio value
10 years
BDX
BDX
● Live price
2.27%
Share price
$154.69
Annual div
$3.51
5Y div CAGR
13.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$1,058.14
Full BDX calculator →
ZBH
ZBH
● Live price
1.08%
Share price
$88.62
Annual div
$0.96
5Y div CAGR
0.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$118.64
Full ZBH calculator →

Portfolio growth — BDX vs ZBH

📍 BDX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDXZBH
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDX + ZBH cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDX pays
ZBH pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDX
Annual income on $10K today (after 15% tax)
$192.91/yr
After 10yr DRIP, annual income (after tax)
$899.42/yr
ZBH
Annual income on $10K today (after 15% tax)
$92.08/yr
After 10yr DRIP, annual income (after tax)
$100.84/yr
At 15% tax rate, BDX beats the other by $798.58/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDX + ZBH for your $10,000?

BDX: 50%ZBH: 50%
100% ZBH50/50100% BDX
Portfolio after 10yr
$24.1K
Annual income
$588.39/yr
Blended yield
2.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BDX right now

BDX
Analyst Ratings
16
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$193.80
+25.3% upside vs current
Range: $170.00 — $215.00
Altman Z
2.1
Piotroski
8/9
ZBH
Analyst Ratings
17
Buy
21
Hold
3
Sell
Consensus: Hold
Price Target
$105.60
+19.2% upside vs current
Range: $89.00 — $122.00
Altman Z
1.7
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDX buys
12
ZBH buys
0
PoliticianChamberTickerTypeAmountDate
Ro Khanna🏢 House$BDX▲ Buy$1,001 - $15,0002025-09-29
Lisa McClain🏢 House$BDX▼ Sell$1,001 - $15,0002025-06-24
Lisa McClain🏢 House$BDX▲ Buy$1,001 - $15,0002025-06-17
Rob Bresnahan🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-15
Thomas H. Kean🏢 House$BDX▲ Buy$1,001 - $15,0002025-05-13
Rob Bresnahan🏢 House$BDX▼ Sell$1,001 - $15,0002025-04-08
Jefferson Shreve🏢 House$BDX▼ Sell$15,001 - $50,0002025-03-05
William R. Keating🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-11
Ro Khanna🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-09
John James🏢 House$BDX▼ Sell$1,001 - $15,0002024-09-04
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDXZBH
Forward yield2.27%1.08%
Annual dividend / share$3.51$0.96
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.5%0.2%
Portfolio after 10y$26.9K$21.2K
Annual income after 10y$1,058.14$118.64
Total dividends collected$5.7K$1.1K
Payment frequencyquarterlyquarterly
SectorHealthcareHealthcare
Analyst consensusBuyHold
Analyst price target$193.80$105.60

Year-by-year: BDX vs ZBH ($10,000, DRIP)

YearBDX PortfolioBDX Income/yrZBH PortfolioZBH Income/yrGap
1← crossover$10,958$257.59$10,809$108.54+$149.00BDX
2$12,024$299.40$11,675$109.86+$349.00BDX
3$13,214$348.50$12,603$111.13+$611.00BDX
4$14,545$406.26$13,598$112.34+$947.00BDX
5$16,038$474.35$14,663$113.51+$1.4KBDX
6$17,715$554.80$15,804$114.62+$1.9KBDX
7$19,606$650.06$17,026$115.69+$2.6KBDX
8$21,741$763.12$18,335$116.71+$3.4KBDX
9$24,161$897.64$19,736$117.70+$4.4KBDX
10$26,910$1,058.14$21,236$118.64+$5.7KBDX

BDX vs ZBH: Complete Analysis 2026

BDXHealthcare

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Full BDX Calculator →

ZBHHealthcare

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Full ZBH Calculator →
📬

Get this BDX vs ZBH comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDX vs SCHDBDX vs JEPIBDX vs OBDX vs KOBDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.